Skip to Main Content

Acadia Pharmaceuticals (ACAD) either didn’t receive — or is ignoring — the Big Pharma etiquette memo about easing back on egregious drug-price hikes.

During the fourth quarter, the San Diego-based company acknowledged Tuesday night, it took two price increases for Nuplazid, a pill used to quell hallucinations and delusions often experienced by people with advanced Parkinson’s disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED